Review paper
P-113 FIGHT-302: Phase 3 study of first-line pemigatinib vs gemcitabine + cisplatin for cholangiocarcinoma with FGFR2 fusions or rearrangement
Abstract
For advanced cholangiocarcinoma, standard-of-care first-line systemic treatment is gemcitabine + cisplatin. Activating genetic alterations in patients with intrahepatic cholangiocarcinoma provide potential therapeutic targets. Fibroblast growth factor receptor (FGFR) 2 gene fusions or rearrangements drive cholangiocarcinoma tumorigenesis and occur in 10–16% of patients, being almost exclusively confined to patients with intrahepatic...
Paper Details
Title
P-113 FIGHT-302: Phase 3 study of first-line pemigatinib vs gemcitabine + cisplatin for cholangiocarcinoma with FGFR2 fusions or rearrangement
Published Date
Jul 1, 2021
Journal
Volume
32
Pages
S137 - S137
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History